Menu

Zika’s Effects on Babies Can Show Up Later

The CDC finds one in seven children exposed to the virus in utero experiences health problems by age one.

Aug 7, 2018
Kerry Grens

ABOVE: © ISTOCK, AYWAN88

Around 14 percent of babies whose mothers contracted Zika while pregnant ended up with a birth defect, developmental abnormality, or both, according a report released by the US government today (August 7). Some of the symptoms didn’t show up right away when the babies were born, but emerged in later testing.

“The full range of long-term health problems caused by Zika will remain unknown until these babies mature,” according to a summary of the report from the Centers for Disease Control and Prevention (CDC).

The agency collected health data on 1,450 babies at least one year old who were exposed to Zika in utero and born in a US territory. Six percent of the children had a Zika-associated birth defect, but others’ symptoms showed up later in life. Among 822 babies who did not have a birth defect, 14 had a brain abnormality that was revealed in neuroimaging.

See “Mouse Pups Infected With Zika Show Symptoms Into Adulthood

“That happened because their brain was not growing and developing properly” due to the virus, Margaret Honein, director of the Division of Congenital and Developmental Disorders at the CDC, tells NPR.

In the US and its territories, reports of Zika infections tapered off at the beginning of 2017, with very few cases popping up since then. However, this likely isn’t the end of Zika, and outbreaks may re-emerge.

“I think the bottom line is that the Zika story is not over,” Honein tells The Washington Post. “People may feel like it’s behind us. For these children, it’s not over, and we need to know as much as possible so that we can be prepared” for a future outbreak.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!